Integra LifeSciences (NASDAQ:IART) Releases Q1 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) updated its first quarter 2025 earnings guidance on Tuesday. The company provided earnings per share guidance of 0.400-0.450 for the period, compared to the consensus earnings per share estimate of 0.560. The company issued revenue guidance of $375.0 million-$385.0 million, compared to the consensus revenue estimate of $411.7 million. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Citigroup upped their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a report on Tuesday, November 5th. Morgan Stanley started coverage on shares of Integra LifeSciences in a research note on Monday, December 2nd. They issued an “underweight” rating and a $20.00 target price on the stock. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $23.00.

Integra LifeSciences Stock Down 1.7 %

Shares of NASDAQ IART traded down $0.40 during midday trading on Thursday, reaching $23.21. 223,228 shares of the company’s stock traded hands, compared to its average volume of 600,608. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. The stock’s 50 day simple moving average is $23.74 and its 200-day simple moving average is $21.84. Integra LifeSciences has a one year low of $16.81 and a one year high of $41.17. The company has a market cap of $1.79 billion, a price-to-earnings ratio of -255.92, a P/E/G ratio of 0.73 and a beta of 1.17.

Integra LifeSciences (NASDAQ:IART) last posted its earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $442.65 million during the quarter, compared to analysts’ expectations of $445.15 million. During the same quarter in the prior year, the company posted $0.89 earnings per share. Integra LifeSciences’s revenue for the quarter was up 11.5% compared to the same quarter last year. On average, analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Insider Activity at Integra LifeSciences

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at approximately $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 3.10% of the stock is currently owned by corporate insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.